Insight

Aaron Goodman: Patients with Erdheim Chester disease should be started on much lower doses of targeted therapies

Photo from Aaron Goodman/X

Mar 3, 2024, 17:02

Aaron Goodman: Patients with Erdheim Chester disease should be started on much lower doses of targeted therapies

Aaron Goodman shared an X post by Razelle Kurzrock, Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center, adding:

“Patients with Erdheim Chester disease should be started on much lower doses of targeted therapies (BRAFi, MEKi). This disease is like CML with exquisite and deep responses to single-agent targeted therapy. Just start low (I usually start 25 to 50% dose reduction).”

Quoting Razelle Kurzrock’s post:

“Patients with Erdheim Chester Disease need lowered doses — but they respond.”

Source: Aaron Goodman/X and Razelle Kurzrock/X

Aaron Goodman is a Hematologist/ Oncologist and an Associate Professor of Medicine at the University of California, San Diego. He is a member of the National Comprehensive Cancer Network (NCCN) guideline committee for both cutaneous NHLs and T-cell NHLs. Dr. Goodman is a well-known physician-scientist, educator, advocate, and social media influencer.

Aaron Goodman BRAF inhibitor cancer CML Erdheim Chester disease Ila Saunders Medical College of Wisconsin Cancer Center MEK inhibitor OncoDaily Oncology Razelle Kurzrock targeted therapy The University of California San Diego

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage